ft 27 nov 92 technolog stalk enemi within thousand peopl die everi year infect resist antibiot clive cookson continu seri drug discoveri look new way kill germ infecti diseas emerg seriou threat health advanc industrialis countri us nation academi scienc say alarm new report particular caus concern grow resist microb antibiot drug na report follow seri call american microbiologist epidemiologist end era complac infecti ill medic commun societi larg tend view acut infecti diseas problem past said robert shope yale univers assumpt wrong claim victori soon drug industri listen view attract grow commerci potenti antibiot sale acceler fast sluggish spell 1980 stewart adkin pharmaceut analyst shearson lehman estim worldwid market antibiot worth dollar 20bn pound 13bn last year 12 per cent 1990 drug resist key driver market said soon penicillin came use 1940 microbiologist began find resist strain emerg simpl result select evolut bacteria surviv cours antibiot treatment one natur resist suscept sister wipe howev pharmaceut research manag avert penicillin resist crisi discov new class antibiot cephalosporin tetracyclin aminoglycosid carbapenem doctor could use instead bacteria becam resist one drug doctor could prescrib anoth bacteria approach come end road world peopl die result infect respond 160 differ antibiot market problem exacerb excess use although antibiot attack bacteria rather virus still mani doctor will prescrib broad spectrum antibiot patient ill defin symptom almost certainli viral origin veterinari industri contribut dose farm anim unnecessari antibiot estim total cost antibiot resist us rang dollar 30bn year organ resist seriou problem includ streptococci staphylococci enterococci pseudomona mycobacterium tuberculosi mani other caus horrifi rang diseas pneumonia mening peopl like fall victim resist organ go hospit us 5 per cent patient 2m peopl pick infect enter hospit 20 000 die everi year accord na report everi year hospit acquir infect account dollar 5bn dollar 10bn addit medic relat expens meanwhil drug compani continu develop novel antibiot use microb resist old one sever promis newcom come japan lorabid discov kyowa hakku launch us eli lilli first new class oral antibiot broad spectrum activ carbacephem pharmaceut analyst say lorabid could dollar 1bn year blockbust lilli lead us antibiot manufactur uk ici high hope meropenem discov sumitomo develop anglo japanes collabor meropenem due launch europ 1994 belong relat class antibiot carbapenem also wide rang anti bacteri activ smithklin beecham anglo us group taken lead tackl resist head bacteria protect mani antibiot produc enzym call beta lactamas destroy antibiot chanc destroy long search sb found substanc clavulan acid inhibit product beta lactamas bacteria sb combin clavulan acid amoxyllin well establish deriv penicillin creat augmentin augmentin cure wide rang infect resist amoxyllin sale rise rapidli year next augmentin expect overtak lilli ceclor becom world best sell brand antibiot accord sb resist augmentin yet emerg drug mean power enough deal bacteria sb scientist develop combin antibiot beta lactamas inhibitor promis potent wide rang time sever small pharmaceut biotechnolog compani work radic solut resist problem use natur peptid small protein molecul produc live creatur frog insect bacteria chemic defenc microb basi develop altern bacteriocid drug peptid go variou name bacteriocin magainin cecropin work quit differ way convent antibiot kill bacteria punch hole cell wall gut spill david guttman chief execut appli microbiolog put far difficult bacteria evolv resist extern attack antibiot interfer inner work appli microbiolog biotechnolog compani base new york develop drug base nisin peptid produc lactococcu bacteria milk kill compet microb nisin manufactur uk aplin amp barrett own appli microbiolog use food preserv 30 year without resist emerg combin nisin chemic known chelat agent scientist appli microbiolog creat power drug broad spectrum anti bacteri activ one target helicobact pylori import caus peptic ulcer magainin pharmaceut base pennsylvania focus defens peptid frog secret skin compani first magainin drug topic antibiot skin infect start human clinic trial last month uk proteu use comput aid molecular design techniqu chang structur peptid make potent longer last natur chemic drug shown promis laboratori test yet readi human trial limit mani peptid broken human digest system therefor cannot taken mouth give system effect magainin develop modifi version could system antibiot jay moorin chief execut excit recent discov molecul squalamin circul blood sand shark broadest spectrum natur antibiot everi seen absorb oral say entir new antibiot squalamin may help turn back tide infecti diseas next centuri human anim health sector must learn curb excess use antibiot articl drug treat depress appear shortli christma world sale top 10 antibiot 1991 estim product origin princip brand dollar bn ampicillin smithklin beecham mani 2 00 amoxicillin smithklin beecham mani 1 40 cefaclor lilli ceclor 1 10 amoxicillin clavulan acid smithklin beecham augmentin 0 90 ciprofloxacin bayer cipro 0 85 ceftriaxon roch rocephin 0 80 erythromycin abbott mani 0 80 cefuroxim glaxo zinnat zinacef 0 65 cefalexin lilli mani 0 60 ceftazidim glaxo fortaz 0 60 sourc michael barber amp associ